THE synergistic action of the combination ofsulphonamides and 2-4-diamino-pyrimidine compounds against the gonococcus has been demonstrated clinically by Csonka and Knight (1967 Study of the records of 100 male patients who had returned for observation after treatment of gonorrhoea with 900,000 units procaine penicillin intramuscularly daily for 3 days, showed that 94 had been cured and six relapsed. In the present study, 23 of those patients whose infection relapsed after sulphamethoxazole plus trimethoprim treatment were immediately treated with the same regimen of penicillin, and of these, 22 were cured and one relapsed (Table) .
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group.bmj.com on April 11, 2017 -Published by http://sti.bmj.com/ Downloaded from produced a similar state in fifteen out of the 33 cases of relapse; additionally two of four cases of failure among the ten treated with pyrimethamine + sulphamethoxazole showed the carrier state. No adverse reactions to the drugs were noted. Because trimethoprim was known to be ineffective in gonorrhoea it was not considered ethical to use the related substance pyrimethamine alone.
Discussion
We found that trimethoprim plus sulphamethoxazole was not as effective in the treatment of gonorrhoea as Csonka and Knight (1967) appear to have found it. This could have been due to our recognition of the asymptomatic carrier state, detectable only in the early stages, at the end of the first or second week, by routine examination of urethral smears. Relapses in their series occurred within 7 days of beginning treatment, and in all such cases, the possibility of re-infection had been excluded (Curtis, 1965) . If those cases of relapse which were asymptomatic are excluded from our series, it is interesting to note that our failure rates are similar to those of Csonka and Knight (1967) . The finding of decreased efficacy coupled with a tendency to produce a carrier state in patients liable to default, makes the drug combination unsuitable for routine clinic use in treatment of gonorrhoea. The argument is underlined by the fact that our standard treatment with 09 m.u. procaine penicillin given intramuscularly daily for 3 days produces a 6 per cent. relapse rate, as against a 38 per cent. failure rate with the drug combination. The similar cure rates relating to penicillin, either as obtained in retreatment of relapsing cases in the present study or as derived from the retrospective study, suggest that the range of sensitivities of the strains of gonococci remained substantially unchanged.
In our opinion, the resistance of gonococci to sulphamethoxazole alone may be unrelated to their response to the combination of trimethoprim plus sulphamethoxazole; in our cases the combination was as effective in the sulphamethoxazole resistant cases as it was in the cases undergoing initial treatment. This could imply that sulphonamides may be inhibiting the formation of folic acid (or the later derivative in its chain) in the bacterial cell at more than one site (Wright, 1969) .
Our clinical results were foreshadowed by the work in vitro of Garrod and Waterworth (1968) , in which the minimum inhibitory concentrations of each agent and of the combination were separately determined, but it is emphasized that in our series trimethoprim plus sulphamethoxazole could be used to treat cases of gonorrhoea clinically resistant to sulphamethoxazole alone.
Inhibition of enzyme folate reductase seems to be a common property of all 2-4-diamino-pyrimidine compounds. Differences in activity of these compounds against a given target organism occur either because of slightly altered enzyme specificity or because of differences in pharmacodynamic properties (Bushby and Hitchings, 1968) . These latter properties were the main consideration in selecting trimethoprim rather than pyrimethamine as an antibacterial agent (Lennox-Smith, 1968) .
However, we decided that pyrimethamine plus sulphamethoxazole was worthy of a trial; first because of a similarity between the chemical structures of pyrimethamine and trimethoprim (Figure) ; secondly because pyrimethamine is known to be potentiated by sulphonamides, though the relevant study related to protozoal infections (Hurly, 1959; Wettingfeld, Rowe, and Eyles, 1956) ; and lastly because, in considering the effect against gonococci, small amounts of trimethoprim were found effective in potentiating much larger quantities of sulphonamides (Bushby, 1965; Waterworth, 1966) than was the case with other organisms (Hitchings, 1966) methamine. This last effect occurred despite the fact that the absolute degree of potentiation ('FIC') was less than that occurring with other organisms (Bushby and Barnett, 1967) .
However, in practice, it was found in the present trial that pyrimethamine plus sulphamethoxazole was only moderately effective in treating gonorrhoea, as was trimethoprim plus sulphamethoxazole, both combinations giving failure rates of the order 30 to 40 per cent. We conclude that it is unjustifiable to employ these drug combinations for routine treatment of gonorrhoea. 
